Newsfeeds - Spark Newswire

2 minute read

Earnings

AVEO Pharmaceuticals’s Return On Capital Employed Insights

Today, 10:19 PM

According to Benzinga Pro data, during Q4, AVEO Pharmaceuticals (NASDAQ:AVEO) posted sales of $17.65 million. Earnings were up 30.03%, but AVEO Pharmaceuticals still reported an overall loss of $7.25 million.

AVEO

3 minute read

50 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 10:19 PM

Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share.

ACMR

4 minute read

Earnings Scheduled For March 14, 2022

By Benzinga Insights

Today, 10:19 PM

Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter.

ACHR

4 minute read

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

By Shanthi Rexaline

Today, 10:19 PM

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.

ACIU

1 minute read

Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer

By Vandana Singh

Today, 10:19 PM

Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present

AVEO

2 minute read

AVEO Oncology Highlights Will Present Long-Term Data From Phase 3 TIVO-3 Study Of FOTIVDA In Third-, Fourth-Line Renal Cell Carcinoma

By Benzinga Newsdesk

Today, 10:19 PM

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) Long-term data from pivotal TIVO-3 study continue to demonstrate

AVEO

25 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 10:19 PM

During Friday's session, 445 companies made new 52-week lows.

AAOI

1 minute read

News

AVEO Pharmaceuticals Filed U.S. Patent Application #20220000858 ‘SE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER’

By Charles Gross

Today, 10:19 PM

View Patent Application Here

AVEO

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 10:19 PM

AVEO

2 minute read

Uncategorized

NiKang Therapeutics And AVEO Oncology Announce Clinical Trial Collaboration And Supply Agreement To Evaluate Combination Of NKT2152, A HIF2α Inhibitor, And FOTIVDA (tivozanib) For The Treatment Of Advanced Clear Cell Renal Cell Carcinoma

By Bill Haddad

Today, 10:19 PM

- Phase 2 Clinical Trial Targeted to Commence in 2022 - NiKang Therapeutics Inc. ("NiKang"), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients

AVEO